Renewed interest in using pharmacological ascorbate (AscH 
Introduction
Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States and is increasing in incidence (1) . Current studies have investigated an entirely new approach, using pharmacological ascorbate as an adjuvant to radiotherapy, to treat pancreatic cancer. Intravenous ascorbate (i.e., ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations (2) , which are in the range cytotoxic to tumor cells (3) (4) (5) . Ascorbate induces oxidative stress and cytotoxicity in pancreatic cancer cells, which seems to be greater in tumor versus normal cells (6) . We have firmly established that pharmacological ascorbate is a prodrug for delivery of hydrogen peroxide (H 2 O 2 ) in vitro and in vivo via its autoxidation (3, 6, 7) . A recent phase I study has showed that pharmacological ascorbate is safe and well tolerated in oncology patients (8) . In addition, phase I studies specifically in pancreatic cancer treatment have showed that pharmacologic ascorbate, combined with standard of care chemotherapy regimens, is safe and well tolerated and may lead to overall clinical benefit (9, 10) .
Ascorbate (AscH À , vitamin C) is a classic donor antioxidant (11) . AscH À scavenges oxidizing free radicals by donating an electron/hydrogen atom forming ascorbate radical (Asc * À ), thereby "repairing" the oxidizing radical. In sequential oneelectron oxidations, AscH À can donate 2 electrons to oxygen resulting in formation of dehydroascorbic acid and H 2 O 2 . The sequential one-electron oxidation of ascorbate can occur via the dianion; Asc 2À auto-oxidizes in the presence of dioxygen to produce the Asc central Mn 3þ to Mn 2þ (18) . The reduction potential correlates with the ability of the Mn 3þ to enter into redox reactions with AscH À (19) . Both AscH À and MnPs are well-known antioxidants and can protect cells against oxidizing species generated as a result of metabolism, disease, and ionizing stimuli like radiation (20) (21) (22) (23) . However, at pharmacologic concentrations, AscH À acts as a pro-oxidant. MnPs increase the flux of AscH À -generated peroxide in vitro (18, 24, 25 
Materials and Methods

Cell culture and reagents
The human pancreatic cancer cell lines MIAPaCa-2, Panc-1, and AsPC-1 were purchased from the American Type Culture Collection and passaged for fewer than 6 months after receipt. No additional authentication was conducted. Mn(III) tetrakis(N-methylpyridinium-4-yl) porphyrin pentachloride (MnT4MPyP), and Mn(III) tetrakis(4-benzoic acid) porphyrin chloride (MnTBAP) were purchased from Axxora Platform. Mn (III) meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin pentachloride (AEOL 10113, MnT2EPyP) was from Dr. James D. Crapo (National Jewish Medical and Research Center, Denver, CO). Because MnPs undergo photooxidation (26) , the solid was stored in colored vials at À20 C, or when dissolved in nanopure water, the solution was stored at 4 C in colored vials. Clonogenic survival, adenovirus transfections, and Western blots were conducted as previously described (6) .
Oxygen consumption via Clark electrode
The ) were delivered subcutaneously into the hind leg of nude mice. The tumors were allowed to grow until they reached between 3 and 4 mm in greatest dimension at 10 days, at which time treatment was initiated. Mice were divided into 4 treatment groups and treated daily for 22 days. The groups included controls that received 1 M NaCl i.p.; ascorbate 4 g/kg i.p.; MnT4MPyP 0.2 mg/kg s.c.; and ascorbate 4 g/kg þ MnT4MPyP 0.2 mg/kg. Tumor size was measured every 3 to 4 days by means of a vernier caliper, and tumor volume was estimated according to the following formula:
where L is the greatest dimension of the tumor, and W is the dimension of the tumor in the perpendicular direction. Animals were sacrificed by CO 2 asphyxiation when the tumors reached 1,000 mm 3 .
Statistical analysis
Statistical significance was determined using an upper tailed, one-sided Student t test, with a value of P < 0.05 considered significant. Combination index (CI) was calculated for AscH À and MnP to determine summation, antagonism, or synergy using the multiple drug interaction model (30) . Dose reduction index (DRI) values were also calculated as described (30, 31) . The 2 variables must be calculated from the same percent of cell killing (30, 31) . For the in vivo studies, the statistical analyses focused on the effects of different treatments on cancer progression. The primary outcome of interest was tumor growth over time. Tumor sizes (mm 3 ) were measured throughout the experiments, resulting in repeated measurements across time for each mouse. A generalized estimating equations model was used to estimate and compare group-specific tumor growth curves. Pairwise comparisons were conducted to identify specific group differences in the growth curves. All tests were two-sided and carried out at the 5% level of significance. Analyses were conducted with SAS version 9.3 (SAS Institute Inc.). ] ss ), consistent with an increased oxidative flux in the system. As seen in Fig. 1 (Fig. 3) . The combination of AscH À (1 mmol/L) with MnT4MPyP (0.5 mmol/L) decreases plating efficiency of MIA PaCa-2 cells from 50 AE 2% in controls to 5 AE 1% (Fig. 3A) . As the dose of MnT4MPyP is increased in combination with AscH À , the plating efficiency decreased. When MIA PaCa-2 cells are exposed to 2 mmol/L MnT4MPyP and 1 mmol/L AscH À , no clones survive (Fig. 3A) . AsPC-1 cells were derived from ascites of a pancreatic cancer patient and are more resistant to gemcitabine (38) and AscH (Fig. 2) . The potentiating effect of MnT2EPyP on AscH À cytotoxicity in MIA PaCa-2 cells (Fig. 3D ) and in AsPC-1 ( Supplementary Fig. S1A ) and Panc-1 cells ( Supplementary Fig. S1B (Fig. 3E ). This effect was also showed in AsPC-1 ( Supplementary Fig. S1C ) and Panc-1 cells (Supplementary Fig. S1D ). The decrease in plating efficiency of various pancreatic cancer lines by the addition of MnPs to AscH À correlates with the OCR (R 2 ¼ 0.62, P ¼ 0.01; Fig. 3F) . Also, the plating efficiency correlates with the concentration of Asc * À present in solution after the addition of MnPs (R 2 ¼ 0.82, P ¼ 0.001; Fig. 3F ). Together, these data show that the enhanced cytotoxicity of AscH À is a function of the MnP's reduction potential and their ability to enhance AscH S2A ) and AsPC-1 cells (Supplementary Fig. S2B) When increased concentrations of MnT2EPyP are used, plating efficiency was reduced to 5%; n ¼ 3. Ã , P < 0.001 vs. controls. E, MnTBAP (0.5, 1, or 2 mmol/L) does not alter MIA PaCa-2 plating efficiency. However, when MnTBAP was combined with AscH À , MIA PaCa-2 plating efficiency was decreased to AE30%; n ¼ 3.
Results
MnPs
Ã , P < 0.001 vs. control. F, the OCR of AscH À when combined with MnPs correlates with log (plating efficiency) in pancreatic cancer cell lines (solid line, R 2 ¼ 0.9, P < 0.05). In solution, [Asc
] in the presence of MnPs (from Fig. 1 ) strongly correlated with log(plating efficiency) in MIA PaCa-2, AsPC-1, and Panc-1 cells (hatched line, R 2 % 0.9, P < 0.05. The (2) below specific points on the graph indicate that 2 identical points at that value.
We then obtained whole blood from human pancreatic cancer patients receiving pharmacologic AscH À (50-125 g AscH À twice a week) as part of a phase I trial. Similar to trends seen in mice, Asc * À was not detected in whole blood drawn from patients prior to being infused with AscH À (Fig. 6B ).
When MnT4MPyP (1.0 mmol/L) was added to pre-infusion blood, EPR detectable Asc an increased AscH À oxidation will lead to an increased flux of
MnT4MPyP enhances ascorbate-induced cytotoxicity in vivo To determine if MnPs could enhance ascorbate-induced cytotoxicity in vivo, we treated mice with preestablished MIA PaCa-2 human pancreatic tumors. There were no differences in weight changes among the 4 treatment groups and none of the animals during the study had to be sacrificed for continued weight loss or cachexia. We also obtained whole blood from separate groups of mice treated with the same combinations. Asc * À was not detected in whole blood drawn from mice treated with saline (Fig. 7A) MnT4MPyP enhanced ascorbate-induced cytotoxicity as animals treated with the combination of ascorbate þ MnT4MPyP had a slower rate of growth in tumors when compared with saline (controls) treatment ( Ã , P < 0.01) or ascorbate alone ( # , P < 0.05; Supplementary Table S2 ). The estimated tumor growth curve is displayed in Fig. 7B . On day 25 of the study, the control group had a mean tumor volume of 491 mm 3 , whereas the ascorbate alone group had a mean tumor volume of 384 mm 3 . In mice treated with the combination of MnT4MPyP and ascorbate, mean tumor volume was 174 mm 3 . 
Control
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No potential conflicts of interest were disclosed. ] ss to 310 nmol/L. n ¼ 3 for each determination. AscH À vs. MnT4MPyP, P < 0.05. AscH À vs. AscH À þ MnT4MPyP, P < 0.01. B, MnT4MPyP combined with pharmacologic ascorbate decreased MIA PaCa-2 tumor growth in nude mice. The MnT4MPyP and ascorbate-treated animals had significantly slower tumor growth when compared with the control and ascorbate groups ( Ã # , P < 0.05, n ¼ 12-16/group, means AE SEM). MIA PaCa-2 tumor cells (2 Â 10 6 ) were delivered subcutaneously into the hind leg of nude mice. On day 25, there was nearly a three-fold decrease in tumor growth in animals receiving the combination when compared with controls.
